Clinical trial
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic…
NCT00365157 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00365157 |
|---|---|
| Title | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction |
| Official title | A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study |
| Enrollment | 132 |
| Start date | Oct 23, 2006 |
| Primary completion | Jul 9, 2025 |
| Completion | Jul 9, 2026 |
| First posted | Aug 17, 2006 |
| Last update posted | Jul 11, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: